Pharmacokinetics of intramuscular and intravenous HBIG: Which implications for practice?

Digestive and Liver Disease Supplements

Volumn 3, Issue 4, 2009, Pages 119-123

  Castells, L ^a   Campos Varela, I ^a   Buti, M ^a   Esteban, R ^a  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

HBIG; Hepatitis B immunoglobulin; Hepatitis B virus; Orthotopic liver transplantation

Indexed keywords

ADEFOVIR; HEPATITIS B ANTIBODY; HEPATITIS B SURFACE ANTIBODY; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B VACCINE; LAMIVUDINE; OMRI HEP B; UNCLASSIFIED DRUG;

AREA UNDER THE CURVE; ARTICLE; BACKACHE; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG ELIMINATION; DRUG ERUPTION; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; HEPATITIS B; HUMAN; IMMUNOPROPHYLAXIS; LIVER TRANSPLANTATION; LOW DRUG DOSE; MYALGIA; PRIORITY JOURNAL; RECURRENCE RISK; REINFECTION; TIME TO MAXIMUM PLASMA CONCENTRATION; UNSPECIFIED SIDE EFFECT; VACCINATION;

EID: 71649083749     PISSN: 15945804     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1594-5804(09)60039-5     Document Type: Article

References (42)

1. Samuel D., Muller R., Alexander G., et al. Liver transplantation in European patients with the hepatitis B surface antigen. N Engl J Med 329 (1993) 1842-1847
2. O'Grady J., Smith H., Davies S., et al. Hepatitis B virus reinfection after orthotopic liver transplantation. J Hepatol 14 (1992) 104-111
3. Brind A., Jiang J., Samuel D., et al. Evidence for selection of hepatitis B virus mutants after liver transplantation through peripheral blood mononuclear cells. J Hepatol 26 (1997) 228-235
4. Zoulim F. Towards an improved and cost-saving prophylaxis of hepatitis B virus recurrence after liver transplantation?. J Hepatol 38 (2003) 850-852
5. Terrault N.A., Zhou S., Combs C., et al. Prophylaxis in liver transplant recipients using a fixed dosing schedule of hepatitis B immunoglobulin. Hepatology 24 (1996) 1327-1333
6. Seehofer D., and Berg T. Prevention of hepatitis B recurrence after liver transplantation. Transplantation 80 Suppl 1 (2005) S120-S124
7. McGory R. Pharmacoeconomic analysis of HBV liver transplant therapies. Clin Transplant 14 Suppl 2 (2000) 29-38
8. Mutimer D. Review article: hepatitis B and liver transplantation. Aliment Pharmacol Ther 23 (2006) 1031-1041
9. Shouval D., and Samuel D. Hepatitis B immune globulin to prevent hepatitis B virus graft reinfection following liver transplantation: a concise review. Hepatology 32 (2000) 1189-1195
10. Tung B.Y., and Kowdley K.V. Hepatitis B and liver transplantation. Clin Infect Dis 41 (2005) 1461-1466
11. Adler R., Safadi R., Caraco Y., et al. Comparison of Immune Reactivity and pharmacokinetics of two hepatitis B Immune globulins in patients after liver transplantation. Hepatology 29 (1999) 1299-1305
12. Burbach G.J., Bienzle U., Neuhaus R., et al. Intravenous or intramuscular anti-HBs immunoglobulin for the prevention of hepatitis B reinfection after orthotopic liver transplantation. Transplantation 63 (1997) 478-480
13. Alonso I., Herreros de Tejada A., et al. Effectiveness of low-dose intramuscular anti-VHB immune globulin in the prophylaxis of viral B hepatitis reinfection after liver transplantation: preliminary report. Transplant Proc 35 (2003) 1850-1851
14. Perrillo R.P., Wright T., Rakela J., et al. A multicenter United States-Canadian trial to assess lamivudine monotherapy before and after liver transplantation for chronic hepatitis B. Hepatology 33 (2001) 424-432
15. Bock C.T., Tillmann H.L., Torresi J., et al. Selection of hepatitis B virus polymerase mutants with enhanced replication by lamivudine treatment after liver transplantation. Gastroenterology 122 (2002) 264-273
16. Dodson S.F., de Vera M.E., Bonham C.A., et al. Lamivudine after hepatitis B immune globulin is effective in preventing hepatitis B recurrence after liver transplantation. Liver Transpl 6 (2000) 434-439
17. Rizzetto M., and Marzano A. Posttransplantation prevention and treatment of recurrent hepatitis B. Liver Transpl 6 Suppl 2 (2000) S47-S51
18. Polak W.G., Gladysz A., and Rotter K. Prevention of hepatitis B recurrence after liver transplantation. Ann Transplant 10 (2005) 11-16
19. Eisenbach C., Sauer P., Mehrabi A., et al. Prevention of hepatitis B virus recurrence after liver transplantation. Clin Transplant 20 Suppl 17 (2006) 111-116
20. Rosenau J., Bahr M.J., Tillmann H.L., et al. Lamivudine and lowdose hepatitis B immune globulin for prophylaxis of hepatitis B reinfection after liver transplantation possible role of mutations in the YMDD motif prior to transplantation as a risk factor for reinfection. J Hepatol 34 (2001) 895
21. Angus P.W., McCaughan G.W., Gane E.J., et al. Combination lowdose hepatitis B immunoglobulin and lamivudine therapy provides effective prophylaxis against posttransplantation hepatitis B. Liver Transpl 6 (2000) 429
22. Han S.H., Martin P., Edelstein M., et al. Conversion from intravenous to intramuscular hepatitis B immune globulin in combination with lamivudine is safe and cost-effective in patients receiving long-term prophylaxis to prevent hepatitis B recurrence after liver transplantation. Liver Transpl 9 (2003) 182
23. Faust D., Rabenau H.F., Allwin R., et al. Cost-effective and safe ambulatory long-term immunoprophylaxis with intramuscular instead of intravenous hepatitis B immunoglobulin to prevent reinfection after orthotopic liver transplantation. Clin Transplant 17 (2003) 254
24. Ferretti G., Merli M., Ginanni Corradini S., et al. Low-dose intramuscular hepatitis B immune globulin and lamivudine for long-term prophylaxis of hepatitis B recurrence after liver transplantation. Transplant Proc 36 (2004) 535-538
25. Gane E., Angus P.W., Strasser S., et al. Lamivudine plus low-dose hepatitis B immunoglobulin to prevent recurrent hepatitis B following liver transplantation. Gastroenterology 132 (2007) 931-937
26. Partovi N., Guy M.W., Ensom M., et al. A study of the pharmacokinetic profile of low-dose hepatitis B immune globulin in long-term liver transplant recipients for chronic hepatitis B infection. Am J Ttranspl 1 (2001) 51-54
27. Hooman N., Rifai K., Hadem J., et al. Antibody to hepatitis B surface antigen through levels and half-lives do not differ after intravenous and intramuscular administration after liver transplantation. Liver Transpl 14 (2008) 435-442
28. Lobo E.D., Hansen R.J., and Balthasar J.P. Antibody pharmacokinetics and pharmacodynamics. J Pharm Sci 93 (2004) 2645-2668
29. Thurmann P.A., Sonnenburg C., Valentova K., et al. Pharmacokinetics of viral antibodies after administration of intravenous immunoglobulin in patients with chronic lymphocytic leukaemia or multiple myeloma. Eur J Clin Pharmacol 57 (2001) 235-241
30. Terrault N.A., Zhou S., Combs C., et al. Prophylaxis in liver transplant recipients using a fixed dosing schedule of hepatitis B immunoglobulin. Hepatology 24 (1996) 1327-1333
31. Rosenau J., Kreutz T., Kujawa M., et al. HBsAg level at time of liver transplantation determines HBsAg decrease and anti-HBs increase and effects HBV DNA decrease during early immunoglobulin administration. J Hepatol 46 (2007) 635-644
32. Buti M., Mas A., Prieto M., et al. A randomized study comparing lamivudine monotherapy after a short course of hepatitis B immune globulin (vid) and lamivudine with long-term lamivudine plus vid in the prevention of hepatitis B virus recurrent after liver transplantation. J Hepatol 38 (2003) 811-817
33. Dodson S.F., Bonham C.A., de Vera M.E., et al. Lamivudine after hepatitis B immune globulin is effective in preventing hepatitis B recurrence after liver transplantation. Liver Transpl 6 (2000) 434-439
34. Wong S.N., Chu C.J., Wai C.T., et al. Low risk of hepatitis B virus recurrence after withdrawal of long-term hepatitis B immunoglobulin in patients receiving maintenance nucleos(t)ide analogue therapy. Liver Transpl 13 (2007) 374-381
35. Chan H.L., Chui A.K., Lau W.Y., et al. Outcome of lamivudine resistant hepatitis B vírus mutant post-liver transplantation on lamivudine monoprophylaxis. Clin Transplant 18 (2004) 295-300
36. Sanchez-Fueyo A., Rimola A., Grande L., et al. Hepatitis B immunoglobulin discontinuation followed by hepatitis B virus vaccination: A new strategy in the prophylaxis of hepatitis B virus recurrence after liver transplantation. Hepatology 31 (2000) 496-501
37. Angelico M., Di Paulo D., Trinito M.O., et al. Failure of reinforced triple course of hepatitis B vaccination in patients transplanted for HBV-related cirrhosis. Hepatology 35 (2002) 176-181
38. Lampertico P., Vigano M., Manenti E., et al. Low resistance to adefovir combined with lamivudine: a 3-year study of 145 lamivudine resistant hepatitis B patients. Gastroenterology 133 (2007) 1445-1451
39. Schiff E., Lai C.L., Hadziyannis S., et al. Adefovir dipivoxil for waitlisted and post-transplantation patients with lamivudine-resistant hepatitis B: final long-term results. Liver Transpl 13 (2007) 349-360
40. Angus P.W., Patterson S.J., Strasser S., et al. A randomized study of adefovir dipivoxil in place of HBIG in combination with Lamivudine as post-liver transplantation hepatitis B prophylaxis. Hepatology 48 (2008) 1460-1466
41. Terrault N., Roche B., and Samuel D. Management of the hepatitis B virus in the liver transplantation setting: a European and an American perspective. Liver Transpl 11 (2005) 716-732
42. Angus P.W., and Patterson S.J. Liver transplantation for hepatitis B: what is the best hepatitis B immune globulin/antiviral regimen?. Liver Transpl 14 (2008) S15-S22